Copeptin and Troponin for fast Acute Myocardial Infarction (AMI) rule-out with the 1st blood sample. The interventional clinical trial BIC-8 demonstrated that it is safe to discharge suspected AMI patients who have normal levels of Troponin and Copeptin at admission.

  • You want to test Copeptin?
    You want to test Copeptin?

    Contact us for more information.

  • Focus: Neurosurgery
    Focus: Neurosurgery

    The recently published “Postoperative copeptin concentration predicts diabetes insipidus after pituitary surgery” confirms that Copeptin may become a novel tool for early goal-directed management of patients undergoing pituitary surgery.


Electrolyte Disorders

Keyvisual Electrolyte Disorders

Copeptin – the better vasopressin

Because of technical limitations of AVP assays, vasopressin concentrations were rarely measured in the past. The vasopressin surrogate Copeptin now opens the possibility
to take full advantage of the hormone’s diagnostic potential. Copeptin is routinely measured for differentiate all forms of diabetes insipidus from primary polydipsia with an easy to use assay technology at highest sensitivity and stability.

Early rule-out of AMI

Keyvisual Early rule out of AMI

Copeptin Safe AMI Rule-Out on admission with the 1st blood draw. Now recommended in the 2015 ESC Guidelines.

In this era of overcrowded emergency departments (EDs), measuring Copeptin along with Troponin (Tn) in the first blood draw now is proven to safely increase ED discharge, and significantly decrease hospital and ED/chest pain unit (CPU) lengths-of-stay, in patients presenting with signs and symptoms of Acute Coronary Syndrome (ACS). 


Latest News